Corcept Therapeutics
Corcept is leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators. In 2012, we received FDA approval of Korlym (mifepristone), the first approved treatment for hypercortisolism (Cushing's syndrome). Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advancing the possibilities of cortisol modulation. The Sr. Product Manager will support the development and lead the execution of unbranded patient marketing initiatives for the endocrine division and contribute to the pre-launch & launch initiatives for the expansion of the franchise in late 2025.
Corcept appreciates the commitment and hard work of all our team members as we strive to discover and develop novel treatments for patients with serious unmet medical needs.
Website
corcept.com
Company Size
251-500 employees
Location
Redwood City, CA
Industry
Pharmaceutical and Medicine Manufacturing
Other opportunities you might be interested in
McKesson
CAS
Analog Devices
Arm Holdings
McCain Foods
Amperity